Wrap and NewsImmuron Limited (ASX: IMC) fundraising open

Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, announced entering into an underwritten public offer of 500,000 American Depositary Shares. Each ADS represents 40 ordinary shares of the Company with a public offering price of USD$4.00 per ADS. The Company plans to issue the securities under the 15% capacity under Listing Rule 7.1, and the offering is expected to be approximately USD$2,000,000.